Disease: Philadelphia chromosome positive chronic myelogenous leukemia ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0279543
Disease: Philadelphia chromosome positive chronic myelogenous leukemia
Philadelphia chromosome positive chronic myelogenous leukemia 		0.100 GeneticVariation disease BEFREE The BCR-ABL1 fusion gene is the driver mutation of Philadelphia chromosome-positive chronic myeloid leukemia (CML). 31707540 2020
CUI: C0279543
Disease: Philadelphia chromosome positive chronic myelogenous leukemia
Philadelphia chromosome positive chronic myelogenous leukemia 		0.100 GeneticVariation disease BEFREE Key genetic aberrations include the BCR-ABL1 gene rearrangement in Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and JAK2/MPL/CALR aberrations in Philadelphia chromosome-negative MPNs. 29951914 2018
CUI: C0279543
Disease: Philadelphia chromosome positive chronic myelogenous leukemia
Philadelphia chromosome positive chronic myelogenous leukemia 		0.100 Biomarker disease BEFREE Using another human CML cell line (KCL22 cells) and BCR/ABL+ Ba/F3 cells (mimicking Philadelphia chromosome-positive CML cells) confirmed that suppressing S6K1 and activating AMPK increased sensitivity to TKI. 29121435 2018
CUI: C0279543
Disease: Philadelphia chromosome positive chronic myelogenous leukemia
Philadelphia chromosome positive chronic myelogenous leukemia 		0.100 Biomarker disease BEFREE Purpose Bosutinib is a potent dual SRC/ABL kinase inhibitor approved for adults with Philadelphia chromosome-positive chronic myeloid leukemia (CML) resistant and /or intolerant to prior therapy. 29091516 2018
CUI: C0279543
Disease: Philadelphia chromosome positive chronic myelogenous leukemia
Philadelphia chromosome positive chronic myelogenous leukemia 		0.100 AlteredExpression disease BEFREE The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib. 28466557 2017
CUI: C0279543
Disease: Philadelphia chromosome positive chronic myelogenous leukemia
Philadelphia chromosome positive chronic myelogenous leukemia 		0.100 GeneticVariation disease BEFREE Patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase with MR<sup>4.5</sup> (BCR-ABL1⩽0.0032% on the International Scale (BCR-ABL1<sup>IS</sup>)) and ⩾2 years of frontline nilotinib therapy were enrolled. 28218239 2017
CUI: C0279543
Disease: Philadelphia chromosome positive chronic myelogenous leukemia
Philadelphia chromosome positive chronic myelogenous leukemia 		0.100 GeneticVariation disease BEFREE Leukemia cells escape BCR-ABL-targeted therapy by developing mutations, such as T315I, in the p210(BCR-ABL) fusion protein in Philadelphia chromosome-positive chronic myeloid leukemia (CML). 26846820 2016
CUI: C0279543
Disease: Philadelphia chromosome positive chronic myelogenous leukemia
Philadelphia chromosome positive chronic myelogenous leukemia 		0.100 Biomarker disease BEFREE Nilotinib is a BCR-ABL kinase inhibitor approved for the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia (CML). 23609856 2014
CUI: C0279543
Disease: Philadelphia chromosome positive chronic myelogenous leukemia
Philadelphia chromosome positive chronic myelogenous leukemia 		0.100 Biomarker disease BEFREE BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. 20537386 2010
CUI: C0279543
Disease: Philadelphia chromosome positive chronic myelogenous leukemia
Philadelphia chromosome positive chronic myelogenous leukemia 		0.100 GeneticVariation disease BEFREE Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia. 20015884 2010
CUI: C0279543
Disease: Philadelphia chromosome positive chronic myelogenous leukemia
Philadelphia chromosome positive chronic myelogenous leukemia 		0.100 GeneticVariation disease BEFREE Here we show that in vivo application of targeted nonvirally delivered synthetic bcr-abl siRNA in a female patient with recurrent Philadelphia chromosome positive chronic myeloid leukemia (CML) resistant to imatinib (Y253F mutation) and chemotherapy after allogeneic hematopoietic stem cell transplantation can silence the expression of bcr-abl gene. 19301661 2009
CUI: C0279543
Disease: Philadelphia chromosome positive chronic myelogenous leukemia
Philadelphia chromosome positive chronic myelogenous leukemia 		0.100 Biomarker disease BEFREE Ras pathways are also important downstream effectors of several receptor tyrosine kinases localized in the cell membrane, most notably the BCR-ABL fusion protein seen in patients with Philadelphia chromosome positive chronic myelogenous leukemia. 17604501 2007
CUI: C0279543
Disease: Philadelphia chromosome positive chronic myelogenous leukemia
Philadelphia chromosome positive chronic myelogenous leukemia 		0.100 Biomarker disease BEFREE We identified 243 patients with Philadelphia (Ph) chromosome-positive chronic myeloid leukemia (CML) who had BCR-ABL transcripts monitored by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) after allogeneic stem cell transplantation for a median of 84.3 months. 16449534 2006
CUI: C0279543
Disease: Philadelphia chromosome positive chronic myelogenous leukemia
Philadelphia chromosome positive chronic myelogenous leukemia 		0.100 Biomarker disease BEFREE BCR/ABL fusion tyrosine kinase is responsible for the initiation and maintenance of the Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and a cohort of acute lymphocytic leukemias. 16219545 2005
CUI: C0279543
Disease: Philadelphia chromosome positive chronic myelogenous leukemia
Philadelphia chromosome positive chronic myelogenous leukemia 		0.100 AlteredExpression disease BEFREE Most patients with Philadelphia chromosome positive CML express either the e13a2 (b2a2) or e14a2 (b3a2) MBCR-ABL mRNA. 16109618 2005
CUI: C0279543
Disease: Philadelphia chromosome positive chronic myelogenous leukemia
Philadelphia chromosome positive chronic myelogenous leukemia 		0.100 Biomarker disease BEFREE Fluorescence in situ hybridization (FISH) analysis of lymph node touch smears also disclosed bcr/abl gene fusion signals in the blasts of all patients, confirming that the blasts were derived from Philadelphia chromosome-positive CML. 15871725 2005
CUI: C0279543
Disease: Philadelphia chromosome positive chronic myelogenous leukemia
Philadelphia chromosome positive chronic myelogenous leukemia 		0.100 Biomarker disease BEFREE Imatinib mesylate has been useful in the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia and B cell acute lymphoblastic leukemia through the inhibition of BCR-ABL tyrosine kinase activity. 15505216 2004
CUI: C0279543
Disease: Philadelphia chromosome positive chronic myelogenous leukemia
Philadelphia chromosome positive chronic myelogenous leukemia 		0.100 GeneticVariation disease BEFREE Deletion of the 5'ABL region in Philadelphia chromosome positive chronic myeloid leukemia: frequency, origin and prognosis. 12952226 2003
CUI: C0279543
Disease: Philadelphia chromosome positive chronic myelogenous leukemia
Philadelphia chromosome positive chronic myelogenous leukemia 		0.100 GeneticVariation disease BEFREE The objective of this study was to characterize the ABL1-BCR fusion gene in 76 BCR-ABL1-positive chronic myeloid leukemia (CML) patients regarding expression as well as genomic status, to assess the frequency of ABL1-BCR gene deletion in these patients, which has been reported to be an adverse prognostic factor in Philadelphia chromosome-positive CML. 11979553 2002
CUI: C0279543
Disease: Philadelphia chromosome positive chronic myelogenous leukemia
Philadelphia chromosome positive chronic myelogenous leukemia 		0.100 AlteredExpression disease BEFREE Aberrant BCR-ABL transcript with intronic insertion in a patient with philadelphia chromosome-positive chronic myeloid leukemia: implications for disease progression. 11378554 2001
CUI: C0279543
Disease: Philadelphia chromosome positive chronic myelogenous leukemia
Philadelphia chromosome positive chronic myelogenous leukemia 		0.100 Biomarker disease BEFREE The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage. 10985361 2000
CUI: C0279543
Disease: Philadelphia chromosome positive chronic myelogenous leukemia
Philadelphia chromosome positive chronic myelogenous leukemia 		0.100 GeneticVariation disease BEFREE A novel BCR-ABL rearrangement in a Philadelphia chromosome-positive chronic myelogenous leukaemia variant with thrombocythaemia. 9519786 1998
CUI: C0279543
Disease: Philadelphia chromosome positive chronic myelogenous leukemia
Philadelphia chromosome positive chronic myelogenous leukemia 		0.100 GeneticVariation disease BEFREE The positions of the breakpoint within the breakpoint cluster region (bcr) on the bcr-abl gene in 22 chronic-phase cases of Ph1-positive CML were determined using conventional Southern blots, and the splicing pattern were also determined the species of the fused bcr-abl mRNA in 79 CML cases using the polymerase chain-reaction procedure (RT-PCR). 8374529 1993
CUI: C0279543
Disease: Philadelphia chromosome positive chronic myelogenous leukemia
Philadelphia chromosome positive chronic myelogenous leukemia 		0.100 GeneticVariation disease BEFREE BCR-ABL rearrangements in children with Philadelphia chromosome-positive chronic myelogenous leukemia. 1932752 1991
CUI: C0279543
Disease: Philadelphia chromosome positive chronic myelogenous leukemia
Philadelphia chromosome positive chronic myelogenous leukemia 		0.100 Biomarker disease BEFREE In Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphocytic leukemia cells the bcr and c-abl genes are reorganized and transcripts composed of both genes are expressed. 2160631 1990